Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study.

Andrew M Evens, Joseph M Connors,Anas Younes,Stephen M Ansell,Won Seog Kim,John Radford,Tatyana Feldman,Joseph Tuscano,Kerry J Savage,Yasuhiro Oki,Andrew Grigg,Christopher Pocock,Monika Dlugosz-Danecka,Keenan Fenton,Andres Forero-Torres,Rachael Liu,Hina Jolin,Ashish Gautam,Andrea Gallamini

Haematologica（2021）

引用 23|浏览28

暂无评分

摘要

Effective and tolerable treatments are needed for older patients with classical Hodgkin lymphoma (cHL). We report results for older patients with cHL treated in the large phase III ECHELON-1 study of frontline brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). Modified progression-free survival (PFS) per independent review facility (IRF) for older versus younger patients (aged ≥60 versus.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要